The Course of Alcoholic Cirrhosis of The Liver in a Patient with COVID-19
https://doi.org/10.20514/2226-6704-2022-12-3-234-239
Abstract
This article presents the features of the course of liver cirrhosis (LC) in a patient with a new coronavirus infection. The patient had no specific respiratory symptoms of COVID-19 (CoronaVirus Disease 2019), and the reason for outpatient examination for SARS-CoV-2 (severe acute respiratory syndrome coronavirus) RNA was the presence of these symptoms in relatives. Previously, patient E. had been undergoing in-patient examination and treatment for abdomen volume build-up against the background of prolonged alcoholization, and was diagnosed with alcoholic class B LC according to Child-Pugh classification. Conservative therapy was administered, and the patient was discharged with regression of ascites. Within a week after SARS-CoV-2 identification, patient E. showed signs of LC decompensation in the form of increasing abdominal volume, which required repeated inpatient treatment, during which portal vein thrombosis (PVT) and progression of chronic liver disease (CLD) in the post-coid period were revealed. Literature data on 30-day mortality in patients with LC against COVID-19 background are presented, as well as my own observations on the example of 580 case histories. Complications of new coronavirus infection in patients with CLD, methods of their correction are considered here. This observation demonstrates the social significance of the problem of COVID-19 incidence in patients with LC, the necessity for screening for COVID-19 in case of the presence of decompensation episodes, as well as active prevention of infection in these patients.
About the Authors
E. Y. Kudashkina
Department of Hospital Therapy named after Academician G.I. Storozhakov Medical Faculty
Russian Federation
Competing Interests:
Russian Federation
Ekaterina Yu. Kudashkina
Moscow
Competing Interests:
The authors declare no conflict of interests
L. Y. Ilchenko
Department of Hospital Therapy named after Academician G.I. Storozhakov Medical Faculty
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
The authors declare no conflict of interests
I. G. Fedorov
Department of Hospital Therapy named after Academician G.I. Storozhakov Medical Faculty; State Clinical hospital named after V.M. Buyanov
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
The authors declare no conflict of interests
References
1. Johns Hopkins University. COVID-19 Data Visualization Center. New Cases of COVID-19 In World Countries. 2021. [Electronic resource]. URL:https://coronavirus.jhu.edu/data/new-cases (date of the application: 29.12.2021).
2. Amin M. COVID-19 and the liver: overview. J Gastroenterol Hepatol. 2021; 3(33): 309-311. doi:10.1097/MEG.0000000000001808.
3. Dawood R., Salum G., El-Meguid M. The Impact of COVID-19 on Liver Injury: COVID-19 and Liver Injury. J Med Sci. 2021; S0002-9629(21)00400-6. doi:10.1016/j.amjms.2021.11.001
4. Ilchenko L.Yu., Nikitin I.G., Fedorov I.G. COVID-19 and Liver Damage. The Russian Archives of Internal Medicine. 2020; 3(10): 188-197. doi.org/10.20514/2226-6704-2020-10-3-188-197. [In Russian].
5. Nikitin I.G., Ilchenko L.Yu., Fedorov I.G. et al. Liver injury in COVID-19: two clinical cases. Almanac of Clinical Medicine. 2020; 6(48): 412-421. doi.org/10.18786/2072-0505-2020-48-053. [In Russian].
6. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 3(5): 245-266. doi:10.1016/S2468-1253(19)30349-8.
7. World Health Organization. 2018 Global status report on alcohol and health. 2018. [Electronic resource]. URL: https://apps.who.int/iris/handle/10665/274603. (date of the application: 29.12.2021).
8. Ramalho R. Alcohol consumption and alcohol-related problems during the COVID-19 pandemic: a narrative review. Australas Psychiatry. 2020; 28(5): 524-526. doi:10.1177/1039856220943024.
9. Ge J., Pletcher M., Lai J. N3C Consortium Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a National COVID cohort collaborative study. Gastroenterology. 2021; 5(161): 1487-1501. doi:10.1053/j.gastro.2021.07.010.
10. Marjot T., Moon A., Cook J. et al. Outcomes following SARSCoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2021; 3(74): 567-577. doi:10.1016/j.jhep.2020.09.024.
11. Babor, T., Fuente, J., Saunders J., Grant M. The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. WHO/MNH/DAT 89.4, World Health Organization, Geneva, 1989.
12. Albillos A., Lario M., Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014; 6(61): 1385-1396. doi:10.1016/j.jhep.2014.08.010.
13. Premkumar M., Devurgowda D., Dudha S. et al. A/H1N1/09 Influenza is Associated With High Mortality in Liver Cirrhosis. J Clin Exp Hepatol. 2019; 9(2): 162-170. doi:10.1016/j.jceh.2018.04.006.
14. Szabo G., Saha B. Alcohol’s Effect on Host Defense. Alcohol Res. 2015; 2(37): 159-170.
15. Kunutsor S., Laukkanen J. Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis. Thromb Res. 2020; 196: 27–30. https://doi.org/10.1016/j.thromres.2020.08.022.
16. Northup P., Garcia-Pagan J., Garcia-Tsao G. et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 1(73): 366-413. doi:10.1002/hep.31646.
17. Turon F., Driever E., Baiges A. et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors, J Hepatology. 2021; 6(75): 1367-1376. doi:10.1016/ j.jhep.2021.07.020.
18. O’Shea R., Davitkov P., Ko C. et al. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology. 2021; 5(161): 1615-1627. doi:10.1053/j.gastro.2021.08.015
19. Rajan S., Khunti K., Alwan N. et al. In the wake of the pandemic: Preparing for Long COVID. Copenhagen (Denmark): European Observatory on Health Systems and Policies. 2021. [Электронный ресурс]. URL:https://www.euro.who.int/en/health-topics/healthemergencies/coronavirus-covid-19/publications-and-technicalguidance/2021/in-the-wake-of-the-pandemic-preparing-for-longcovid-2021 (дата обращения 27.12.2021.).
20. Zeng Q., Yu Z., Ji F. et al. Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study. BMC Infect Dis. 2021; 1(21): 818. doi:10.1186/s12879-021-06572-z.
Review
For citations:
Kudashkina E.Y., Ilchenko L.Y., Fedorov I.G. The Course of Alcoholic Cirrhosis of The Liver in a Patient with COVID-19. The Russian Archives of Internal Medicine. 2022;12(3):234-239. https://doi.org/10.20514/2226-6704-2022-12-3-234-239
Views:
572
Email this article 